Eli Lilly's new Alzheimer's drug is on its way to the FDA

The latest stories trending on MedCity News.

Editor's Pick

Top Story Eli Lilly Alzheimer's Drug Meets Phase 3 Goals, Teeing Up Plans for FDA Filing Patients treated with Eli Lilly Alzheimer's disease drug donanemab showed a 35% slowing in decline compared to those given a placebo. Based on the Phase 3 results, Lilly said it would seek FDA approval for the drug by the end of June. Sponsored Content Edge Impulse's Edge ML Series: Explore how to deploy advanced Edge ML at scale Presented by Edge Impulse Edge Impulse is bringing its Edge ML Series to London and Boston. Discover the benefits of edge ML, ways to differentiate your products, and how to reduce operational costs using AI tools. Only 2 Days Left to Save $200 Hurry, today and tomorrow are your final days to save $200 on INVEST 2023. Don't miss this opportunity to connect and network with the industry's best investors, startups and more.  Register Now!

Featured News

First FDA Approval of an RSV Vaccine Goes to GSK FDA approval of GSK's respiratory syncytial vaccine Arexvy covers adults age 60 and older—an age group at particular risk of developing severe complications from infection. GSK plans to launch Arexvy in time for the 2023/2024 RSV season. Telehealth Companies Applaud DEA for Delaying Telemedicine Restrictions of Controlled Substances The Drug Enforcement Administration received 38,000 comments on its proposed rule that would roll back Covid-19 flexibilities for the prescribing of controlled substances via telemedicine. In response, the DEA chose to temporarily extend the flexibilities, a decision telehealth companies like Bicycle Health and Mindbloom are in support of. Medicare Advantage Must Boost Health – and Fiscal Responsibility By forcing providers to coordinate and take responsibility for the overall health of customers, Medicare Advantage can promote the healthcare change we need. It's a philosophical shift that makes providers think more like insurers and less like businesses that are rewarded for volume, not results. Horizon Taps Solera Health for Condition Management Platform A new partnership between Horizon and Solera will initially focus on services for musculoskeletal conditions, stress, sleep and resilience, tobacco cessation and weight management. Employers who get their insurance through Horizon will be able to select which conditions its population needs care for and then employees will have access to a selection of health tech vendors for these conditions. Healthcare's Recent Cybercriminal Activity Attributed to Ransomware Gangs Cl0p & LockBit Federal officials are sounding the alarm on two ransomware groups that are actively targeting the healthcare sector: Cl0p and LockBit. In recent months, the groups have been exploiting three known software vulnerabilities in cyberattacks they have waged against healthcare businesses across the country.  Magenta Medical Rakes In $55M for 'World's Smallest Heart Pump' Israeli medical device developer Magenta Medical recently closed a $55 million financing round. The new funding will be used primarily to help Magenta attain FDA approval for its flagship product — a percutaneous left ventricular assist device called Elevate.

Resources

Season 2 of MedCity Pivot Podcast Launches with Conversation of Zephyr AI CTO This season, we will be focusing on artificial intelligence in healthcare. Our very first interview is with Jeff Sherman, chief technology officer of Zephyr AI, a company that aims to transform precision medicine from diagnostics to treatment. How exactly does it plan to do that? Listen to find out.  Listen Now

MedCity News • 611 Broadway • New York, NY unsubscribe